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Abstract 
Hepatocyte nuclear factor‑1beta (HNF1β) was initially identified as a liver‑specific transcription factor. It is a home‑
obox transcription factor that functions as a homodimer or heterodimer with HNF1α. HNF1β plays an important role 
in organogenesis during embryonic stage, especially of the liver, kidney, and pancreas. Mutations in the HNF1β gene 
cause maturity‑onset diabetes of the young type 5 (MODY5), renal cysts, genital malformations, and pancreas atrophy. 
Recently, it has been shown that the expression of HNF1β is associated with cancer risk in several tumors, including 
hepatocellular carcinoma, pancreatic carcinoma, renal cancer, ovarian cancer, endometrial cancer, and prostate can‑
cer. HNF1β also regulates the expression of genes associated with stem/progenitor cells, which indicates that HNF1β 
may play an important role in stem cell regulation. In this review, we discuss some of the current developments about 
HNF1β and tumor, the relationship between HNF1β and stem/progenitor cells, and the potential pathogenesis of 
HNF1β in various tumors.
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Background
Hepatocyte nuclear factors (HNFs) are a group of tran-
scription factors that play important roles in regulat-
ing transcription of the liver specific genes. HNFs are 
expressed predominately in the liver and form a compli-
cated network regulating liver development and hepato-
cyte differentiation. However, these transcription factors 
are not restricted to hepatocytes, they are also expressed 
in many other tissues. Nevertheless, the liver is the only 
tissue in which a significant number of different HNFs 
are expressed at the same time [1]. Four major families 
of HNFs have been described. HNF1α and HNF1β, mem-
bers of the HNF1 family contain a POU-homeodomain 
and bind to DNA as homodimers [2]. The HNF3 pro-
teins (HNF3α, β and γ) belong to the forkhead transcrip-
tion factors and contain a 110 amino acid DNA binding 
domain [3]. HNF4 is a member of the nuclear hormone 
receptor family and binds DNA as a homodimer [4]. 
There are two isoforms of HNF4, HNF4α and HNF4γ, 
encoded by two separate genes HNF4A and HNF4G in 
humans [1]. HNF6 contains a bipartite onecut-homeo-
domain sequence and binds to specific DNA sequences 
of numerous target gene promoters [5]. Among these 
HNFs, HNF1β is one of the most important during devel-
opment and tumorigenesis. In this review, we will focus 
on HNF1β, which regulates the expression of genes that 
are expressed in the liver, kidney, and pancreas, and has 
been identified to cause various human diseases.
The HNF1β gene (TCF2) is located on chromosome 
17q12 [6]. The first description of HNF1β mutations 
associated with disease was in 1997. In humans, hete-
rozygous germline mutations in HNF1β cause maturity-
onset diabetes of the young, subtype 5 (MODY5), which 
is associated with congenital abnormalities, including 
polycystic kidneys, an abnormal genital tract, and severe 
pancreatic hypoplasia [7]. HNF1β, also called variant 
HNF1 (vHNF1) or LFB3, is a homeodomain protein that 
plays an essential role in the liver-specific expression of 
many genes during differentiation and development [8]. 
HNF1β binds to DNA as a homodimer or heterodimer 
with the related protein HNF1α [9]. The expression ratio 
of HNF1β is different in each organ. At the adult stage, 
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HNF1β is strongly expressed throughout the biliary sys-
tem, and in several epithelia organized in tubules, such as 
the pancreatic exocrine ducts and the kidney tubules [10]. 
Expression of HNF1β is also seen in the periportal hepat-
ocytes, thymus, genital tract, lung and gut [9, 10]. HNF1β 
is involved in embryonic development and metabolism 
of the kidney, pancreas, liver and biliary system. Recent 
studies have shown that expression of HNF1β is associ-
ated with cancer risk in several tumors, and HNF1β plays 
an important role in tumorigenesis.
HNF1β status in various tumors
Hepatobiliary malignancies
HNF1β has been demonstrated to be associated with the 
risk of hepatocellular carcinoma (HCC). The HNF1 fam-
ily plays a dominant role in liver-specific transcription. 
Hepatocyte differentiation is linked to the expression of 
liver-specific proteins and that the expression patterns 
are controlled primarily at their transcription levels. It 
is suggested that HNF1α and HNF1β may play distinct 
roles in regulating gene expression in differentiation and 
maturity of hepatocytes. Studies showed that cultured 
cells derived from differentiated hepatoma cells express 
HNF1α, whereas cultured dedifferentiated hepatoma 
cells express HNF1β instead of HNF1α. Analysis of the 
expression of HNF1α and HNF1β mRNA HCC tissues by 
RT-PCR assay showed that the ratio of HNF1α/HNF1β 
mRNA is closely linked to histological differentiation of 
HCC [11]. The ratio of HNF1α/HNF1β mRNA is higher 
in well-differentiated cases than in poorly-differentiated 
and undifferentiated cases. There were more HNF1α 
than HNF1β transcripts in well-differentiated HCC, but 
fewer HNF1α than HNF1β transcripts in poorly differ-
entiated HCC. Western blot revealed that the levels of 
HNF1β protein were similar in well and poorly differ-
entiated HCC, but higher than in the surrounding non-
cancerous portions [12]. HNF1β is expressed in hepatic 
endoderm of foregut during embryonic development and 
precedes HNF1α expression. In the process of hepatic 
development and carcinogenesis, members of the HNF1 
family regulates the activity of the AFP promoter. Shim 
et al. examined the expression of alphafetoprotein (AFP), 
HNF1α, and HNF1β with immunohistochemistry in 
HCC tumor [13]. The results showed that expression of 
HNF1β was related to a serum AFP level and AFP expres-
sion. Upstream regulation of AFP expression by HNF1β 
at the transcriptional level may operate specifically dur-
ing the course of HCC progression following recurrence. 
The expression of HNF1β in tumor tissue could predict 
recurrence and HCC-specific death after transplanta-
tion [13]. HNF1β also plays an important role in the 
regulatory network in mouse liver cells. When HNF1β 
is suppressed by siRNA, the expression level of HNF4α, 
HNF1α, HNF3 (HNF3α, β and γ), and HNF6 are sig-
nificantly downregulated [14]. In mouse hepatoma cells, 
HNF1β regulated many genes. Albumin, α-fetoprotein, 
insulin-like growth factor binding protein 1 and HNF1 
genes were downregulated by RNAi of HNF1β, while 
alcohol dehydrogenase 2, α1-antitrypsin, α-fibrinogen 
and apolipo-protein AII genes were upregulated [14]. 
However, the study of HNF1β and HCC is limited. Thus, 
further study is still needed to understand the role of 
HNF1β in hepatocarcinogenesis in HCC and clinical use 
of HNF1β expression.
HNF1β is expressed in biliary precursor cells and plays 
a crucial role in extrahepatic biliary development [10]. 
Biliary tract cancer (BTC) originates from epithelial 
cells of the hepatic biliary duct system and the gallblad-
der. Study shows expression of HNF1β is relatively low in 
BTC, and HNF1β is nonessential in the biliary tract can-
cers differentiation and maintenance [15].
Pancreatic cancer
Pancreatic carcinoma is the fourth most common cause 
of death among cancers. In pancreas, HNF1β is a useful 
marker to identify clear cell carcinomas, and its over-
expression may predict worse survival. Kim et  al. [16] 
found that HNF1β was overexpressed in clear cell car-
cinomas and in the clear cell components of ductal car-
cinomas with clear cell features. High expression of 
HNF1β showed worse survival regardless of morphologic 
subtype.
Colorectal cancer
Colorectal cancer (CRC) is the third and fourth most 
common cancer in females and males. Studies have indi-
cated that the accumulation of genetic and epigenetic 
alterations could result in the transformation of normal 
colonic epithelial cells to adenocarcinomas [17]. SILVA 
et al. investigated the epigenetic changes (DNA methyla-
tion) in 24 candidate genes in CRC tumors, and identified 
five candidate hypermethylated (HM) genes as CRC bio-
markers. These genes include RUNX3, PCDH10, SFRP5, 
IGF2 and HNF1β [17]. Thus, HNF1β may be used as a 
biomarker for the detection of early-stage of CRC.
Renal and urinary tract cancer
Several studies suggest a role of HNF1β in tumor for-
mation and various kinds of renal disease. Renal cell 
carcinoma (RCC) accounts for more than 80  % of kid-
ney tumors. Studies found that HNF1β expression was 
reduced in tumor tissue compared with normal kidney 
tissue. HNF1β is essential for the maintenance of well-
ordered renal tissue growth, and downregulation or loss 
of expression is correlated with malignant transforma-
tion and dedifferentiation. HNF1β is a prognostic factor 
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and a potential tumor suppressor, and could be a poten-
tial therapeutic target for RCC [18]. Chromophobe renal 
cell carcinoma (ChRCC) is a rare type of kidney cancer 
and accounts for 5 % of all kidney cancer. Lack of HNF1β 
expression plays an important role in the pathogenesis of 
ChRCC, and may serve as a good diagnostic maker [19]. 
Rebouissou et al. screened for HNF1β inactivation in 35 
renal neoplasms and found biallelic HNF1β inactivation 
in 2 chromophobe renal carcinomas by association of 
a germline mutation and a somatic gene deletion. This 
finding suggested that germline mutations of HNF1β may 
predispose to renal tumors and proposed that HNF1β 
may functions as a tumor suppressor gene in ChRCC 
through a PKHD1 expression control [20]. Gad et  al. 
studied 46 cases of ChRCC, but no mutations were iden-
tified in all coding exons of the HNF1β gene. They found 
that mutations in BHD and TP53 genes but not in HNF1β 
gene were detected in a large series of sporadic ChRCC 
[21]. Papillary renal cell carcinomas make up about 15 % 
of renal cell tumors in surgical series. The HNF1β protein 
is expressed only in differentiating tubules of fetal kidney 
and overexpressed in adult tumors of embryonal origin, 
such as papillary RCCs. The gain and overexpression of 
the HNF1β gene is associated with the delayed tubular 
differentiation in precursor lesions [22]. Clear cell ade-
nocarcinoma (CCA) of the urinary tract is a rare tumor 
that is histologically similar to CCA of the female genital 
tract [23]. Brimo et al. reported that HNF1β was a use-
ful marker in differentiating clear cell adenocarcinomas 
of the bladder/urethra from invasive high-grade transi-
tional/urothelial carcinoma and other types of bladder 
adenocarcinomas and to a lesser extent from nephro-
genic adenomas [8].
Prostate cancer
Prostate cancer is one of the most common male malig-
nancies. Recently, a large study has shown that an HNF1β 
sequence variant confers an increased prostate cancer 
risk. The first report of HNF1β associated with pros-
tate cancer risk was in a genome-wide association study 
(GWAS) searching for sequence variants in 1501 Ice-
landic men with prostate cancer and 11,290 controls, 
and the variant, rs4430796, in HNF1β at chromosome 
17q12 was the earliest loci to be discovered for prostate 
cancer [6]. It was later replicated in two GWAS in the 
UK and the United States [24, 25]. Then a second inde-
pendent variant, rs11649743, located at chromosome 
17q12 and separated by a recombination hotspot from 
the first variant, was subsequently found to be associ-
ated with risk [26]. A large-scale fine mapping study of 
a region on 17q12 associated with prostate cancer con-
firmed the previously established signals and found evi-
dence that additional variants contribute to the risk of 
prostate cancer [27]. In this study, the best model for 
prostate cancer risk in the HNF1β region included five 
SNPs, rs4430796, rs7405696, rs4794758, rs1016990 and 
rs3094509, and these SNPs together capture more of the 
risk associated with this region. Zhang et al. explored the 
loci associated with prostate risk in a Northern Chinese 
population and indicated that AG on HNF1β (rs4430796, 
A) could be associated with PSA increase [28]. Hu et al. 
identified 12 prostate cancer risk genes potentially con-
nected and related to HNF1β. Six of them, BAG1, ERBB4, 
ESR1, HSPD1, NR4A1, and PIK3CG, were found to par-
ticipate in the KEGG pathways. The results indicated that 
the prostate cancer risk role of HNF1β could possibly be 
associated with modulating the relationships between 
androgenic hormone and prostate cancer [29].
Ovarian and endometrial cancer
HNF1β was identified from large-scale gene expression 
studies as being a useful marker of ovarian and uterine 
clear cell carcinomas. Clear cell carcinoma (CCC) of the 
ovary has the worst prognosis of all of the epithelial ovar-
ian cancers. A study has demonstrated that the expres-
sion of HNF1β is significantly upregulated in ovarian 
CCC cell lines, while non-CCC ovarian cancer cell lines 
rarely express this protein, also, reduction of HNF1β 
induced apoptotic cell death in ovarian CCC cell lines 
[30]. HNF1β would be not only an excellent CCC-specific 
molecular marker but also a molecular target for the ther-
apy of ovarian CCC. Yamamoto et al. found that the inci-
dence of HNF1β immunoreactivity differed significantly 
between CCCs and other histology in both the ovary and 
the endometrium, which suggested that HNF1β would be 
an excellent marker for distinguishing CCCs from other 
lesions in both the ovary and the endometrium [31]. It 
was demonstrated by Kao et  al. that the overexpression 
of HNF1β is specific for ovarian CCC among ovarian car-
cinomas [32]. The HNF1β gene plays an important role 
in the biology of ovarian CCC. Knockdown of HNF1β 
in ovarian CCC cells resulted in a significant increase 
in proliferation, while overexpression of HNF1β in the 
serous ovarian cancer cell line caused cell growth to be 
significantly decreased [33]. Downregulation of HNF1β 
could contribute to drug resistance in ovarian cancer 
and that HNF1β may perform its drug resistance-related 
functions through four pathways including ErbB signal-
ing, focal adhesion, apoptosis and p53 signaling [34]. 
Terasawa et  al. observed for the first time that HNF1β 
gene is a target for epigenetic inactivation in ovarian can-
cer. HNF1β was methylated in 53 % of ovarian cancer cell 
lines and in 26 % of primary ovarian cancers (especially 
in the non-clear cell types), resulting in loss of the gene’s 
expression. Restoration of HNF1β expression induced 
expression of HNF4α, a transcriptional target of HNF1β, 
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indicating that epigenetic silencing of HNF1β leads to 
alteration of the hepatocyte nuclear factor network in 
tumours [35]. Shen et  al. found a differential effect of 
HNF1β on the serous and clear cell subtypes of ovarian 
cancer, a loss-of-function role in serous and a gain-of 
function role in clear cell ovarian cancers, and variants 
in this gene differentially affect genetic susceptibility to 
these subtypes [36].
Endometrial cancer is the most common gyneco-
logical cancer in developed countries. A genome-wide 
association study identified single nucleotide polymor-
phisms in HNF1β associated with endometrial can-
cer risk in women of European background [37]. SNP 
rs4430796 was identified as an endometrial cancer sus-
ceptibility locus close to HNF1β on chromosome 17q. 
Setiawan et al. provided additional evidence that HNF1β 
is involved in endometrial cancer etiology [38]. The 
HNF1β SNPs (rs4430796 and rs7501939) were associ-
ated with endometrial cancer risk in two independent 
studies and that the associations were observed across 
multiple racial/ethnic groups [38]. A recent genome-
wide association study replicated previously identified 
associations with genetic markers near the HNF1β locus 
in a multiethnic population from nine studies, but no 
novel variants reached genome-wide significance [39]. In 
endometrial cancer, different from ovarian clear cell car-
cinoma, HNF1β should be used with caution as a diag-
nostic marker because of its lack of specificity [40].
The potential pathogenic mechanisms of HNF1β 
in cancer
Epigenetic processes and epigenetic changes
The aberrant expression of HNF1β in tumors is associ-
ated with epigenetic processes and epigenetic changes. In 
humans, one of the epigenetic mechanisms that regulate 
expression of genes is methylation of the clusters of CpG 
dinucleotides, called CpG islands. A probable mechanism 
of aberrant up-regulation of HNF1β in ovarian clear cell 
carcinoma is hypomethylation of the HNF1β CpG island 
[35]. Terasawa et  al. reported that methylation of the 
HNF1β CpG island was rare in ovarian CCC, but com-
mon in non-CCC ovarian cancers or various cancer cell 
lines [35]. Hypomethylation of the HNF1β CpG island 
probably participates in the up-regulation of HNF1β in 
ovarian CCC. Epigenetic inactivation of HNF1β is also 
seen in colorectal, gastric, and pancreatic cancer cell 
lines, suggesting involvement of epigenetic inactivation 
of HNF1β in tumorigenesis [41]. HNF1β mutations are 
known to affect expression of downstream genes such 
as HNF4α, PKHD1 and UMOD [20]. HNF4α is upregu-
lated by inducing HNF1β expression, which suggests 
alterations in the hepatocyte nuclear factor network can 
be reversed by inducing HNF1β through demethylation 
of the gene [35]. Another potential contributors to the 
HNF1β overexpression are histone acetylation and gene 
amplification. Methylation was associated with histone 
deacetylation, and when treating cells with histone dea-
cetylase inhibitor combined with methyltransferase 
inhibitor, HNF1β expression was synergistically induced 
[35]. Studies showed that homeobox genes, such as the 
TLX1, HOXB13, and HNF1B genes methylation play 
a critical role in the insurgence and/or progression of 
breast cancer [42]. In Sporadic colorectal cancer (CRC), 
hypermethylated gene HNF1β was identified, which 
may be a useful epigenetic marker for non-invasive CRC 
screening [17].
The HNF1β target genes
The pathway with which HNF1β is involved in cancer 
is less understood. HNF1β has been identified as one of 
the most highly overexpressed genes in ovarian CCC. 
In ovarian CCC cell lines, one of the most markedly up-
regulated genes was osteopontin (OPN), which is prob-
ably a direct target gene of HNF1β, since OPN contains 
functional HNF1β binding sites in the promoter region 
[43]. It was reported that OPN expression  is elevated in 
ovarian CCC and is closely associated with HNF1β over-
expression.  HNF1β  is likely to participate in OPN up-
regulation in CCC [44]. OPN has been recognized to play 
important roles in the process of tumorigenesis. OPN 
binds to several cell surface receptors and induces several 
signal transduction pathways, which contribute to tumo-
rigenesis by the inhibition of apoptosis or the activation 
of matrix-degrading proteases [45]. The reduction of 
HNF1β might have caused a reduction of OPN, followed 
by an increase in apoptotic activity. Data showed that 
checkpoint kinase (Chk) 1 protein is persistently activated 
in the HNF1β-overexpressing CCC cells [46]. Chk1 might 
function in the cellular survival pathways that enhance 
DNA damage repair, thereby granting chemoresistance. 
Inhibition of Chk1 selectively abrogates the repair of 
damaged DNA, sensitizes cancer cells to radiotherapy, or 
increases cancer cell death in the presence of p53 muta-
tions [47]. The Chk1 inhibitor might be a novel target 
for developing cancer therapeutics in the HNF1β posi-
tive cells [46]. Pathway enrichment analysis of 36 genes 
which co-occurred with HNF1β, ovarian cancer and drug 
resistance was performed by Li et  al. [34]. Four path-
ways including ErbB signaling, focal adhesion, apoptosis 
and p53 signaling were enriched, suggesting that HNF1β 
may contribute to drug resistance in ovarian cancer via 
those pathways. HNF1β may also play a critical role in 
a cytoprotective effect against forthcoming oxidative 
stress. HNF1β may upregulate OGG1 gene expression 
to counteract ROS mediated mitochondrial dysfunction 
[48]. OGG1 also known as 8-oxoguanine glycosylase 
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is a DNA glycosylase enzyme involved in base excision 
repair. Senkel et al. established a human embryonic kid-
ney cell line (HEK293) expressing HNF1β and identified 
25 HNF1β-regulated genes. Eight of the 25 genes were 
significantly up-regulated in ovarian CCC compared to 
the other ovarian cancer types. The genes SPP1, DPP4, 
SAH, RBPMS, CD24, NID2, LAMB1, RHOB and SOX9 
are deregulated in ovary CCC due to the overexpression 
of HNF1β [43]. The genes dipeptidyl peptidase 4 (DPP4), 
and osteopontin (SPP1) are most likely direct target 
genes, as they contain functional HNF1 binding sites in 
their promoter region. DPP4 plays a major role in glucose 
metabolism and appears to work as a suppressor in the 
development of cancer [49]. RBPMS (RNA binding pro-
tein multiple splicing) may be an HNF1β target involved 
in kidney formation. CD24 is a cell adhesion molecule 
that is identified as a progenitor marker. NID2  encodes 
a member of basement membrane proteins that con-
trol a large number of cellular activities [50].  LAMB1 
(Laminin, beta 1) is a member of noncollagenous con-
stituent of basement members. Sox9 [sex-determining 
region Y (SRY)-box 9 protein] plays critical roles during 
embryogenesis. Sox9 is required for development, dif-
ferentiation, and lineage commitment in various tissues. 
Studies showed that 22 of 54 genes highly up-regulated 
in ovarian CCC were involved in downstream targets of 
HNF1β. These genes include GLRX, GPx3, TST, SOD2, 
NNMT, ANXA4, UGT1A1, DPPIV, ACE2, Collectrin, 
TFPI2, MAP3K5/ASK1, Octamer4, PAX8, G6Pase, GK, 
GLUT2, ALDOB, OPN, and FXYD2 [51]. Genes reported 
to be upregulated by HNF1β include NNMT, ANXA4, 
UGT1A1, FXYD2, TFPI2, MAP3K5/ASK1, G6Pase, GK, 
GLUT2, and mTOR [51]. GLRX (Glutaredoxin), GPx3 
(glutathione peroxidase 3), TST (thiosulfate sulfurtrans-
ferase), SOD2 (superoxide dismutase2), NNMT (Nico-
tinamide N-methyltransferase), ANXA4 (Annexin A4), 
and UGT1A1 (UDP-glycosyltransferase 1 family poly-
peptide A1) are responsible for drug metabolism and 
liver detoxification. DPPIV (Dipeptidyl peptidase IV), 
ACE2 (Angiotensin converting enzyme2), Collectrin, and 
TFPI2 (Tissue factor pathway inhibitor 2) are proteases 
involved in oxidative stress. MAP3K5/ASK1 and mTOR 
are related to signal transduction pathways. Octamer4 
(Octamer-binding transcription factor 4) and PAX8 
(Paired box gene 8) are transcription factors involved in 
oxidative stress. G6Pase (Glucose-6-phosphatase), GK 
(Glucokinase), GLUT2 (Glucose transporter type 2), and 
ALDOB (Aldolase B) are related to metabolism. FXYD2 
(domain-containing ion transport regulator 2) is known 
as the gamma subunit of the Na, K-ATPase. HNF1β also 
regulates the expression of CD44v9, which binds several 
target molecules and specifically regulates cell functions, 
including migration, growth, survival, anti-apoptosis, 
immune response and redox status [52]. In human 
hepatoma cells, HNF4α has been suggested to be directly 
regulated by HNF1β [53]. The HNF1β-dependent path-
way might provide new insights into regulation of glyco-
gen synthesis, detoxification and resistance to anticancer 
agents.
The signaling related to stem cells
HNF1β has been described as a key regulator of biliary 
development and is partially regulated by Notch signal-
ing [54]. The Notch pathway has been implicated in the 
regulation of self-renewal of adult stem cells and differ-
entiation of precursors along a specific cell lineage, in 
normal embryonic development and organogenesis [15]. 
Studies showed that HNF1β expression is regulated by 
Notch2 [54]. Notch2 is a member of the notch family, and 
it is used to isolate, identify and localise pancreatic can-
cer stem-like cells. Studies showed that Notch2+ cells in 
human pancreatic cancer Bxpc-3 and Panc-1 cells have 
the properties of cancer stem cells, with strong tumouri-
genic ability [55]. Gene expression microarray data dem-
onstrated that Notch2 is one of the most upregulated 
genes in a cancer stem cell-like population [56]. Moreo-
ver, aberrant Notch2 signaling induces the formation of 
human liver cancers with HpSC features [57].
HNF1β and stem/progenitor cells
Genes and pathways regulating stem and progenitor cells 
are increasingly recognized in tumorigenesis. Tumors 
may often originate from the transformation of normal 
stem cells, since similar signalling pathways may regulate 
self-renewal in stem cells and cancer cells. According to 
the cancer stem cell (CSC) hypothesis, a few CSC with 
self-renewal and multipotentiality differentiation exist 
in tumors, and these cells can create heterogeneity in a 
tumor through abnormal proliferation and differentia-
tion. In HEK293 cells and ovary CCC, HNF1β activates 
the CD24 gene, a cell surface protein that has recently 
been identified as a marker of the renal progenitor popu-
lation in the uninduced metanephric mesenchyme [43]. 
CD24 is highly expressed in many human cancers [58], 
and is often used to identify and enrich CSCs in cancers 
such as ovarian and pancreatic cancer. High expression 
of CD24 is involved in tumor progression and metastasis. 
SOX9 was down-regulated upon HNF1β overexpression 
in HEK293 cells. SOX9 is overexpressed in a wide range 
of human cancers, particularly, in tissues where it plays 
critical roles in their development and in stem/progeni-
tor cells [59]. SOX9 might contribute to carcinogenesis 
through effects on stem cells. The HNF1β target gene 
osteopontin is also shown to be expressed in progeni-
tor cells. OPN  is overexpressed by liver progenitors in 
humans and mice. OPN upregulation during liver injury 
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is a conserved repair response, and influences liver pro-
genitor cell function [60]. A high OPN expression level 
is associated with poor prognosis and metastasis in sev-
eral cancer patients. The expression of CD44 variant 
forms is regulated by several molecules including OPN. 
CD44 interacts with osteopontin and regulates its cellu-
lar functions leading to tumor progression. HNF1β also 
regulates the expression of CD44v9. CD44 is a multifunc-
tional class I transmembrane glycoprotein with a variety 
of functions including participation in cell adhesion and 
migration as well as modulation of cell–matrix interac-
tions [61]. The majority of cancer cell lines express high 
levels of CD44. CD44 is one of the cell surface mark-
ers associated with cancer stem cells in several types of 
tumor, including breast, prostate, pancreas, ovarian, and 
colorectal cancers [52, 58]. Overexpression of CD44 indi-
cated bad clinical features and poor prognosis.
In liver development, HNF1β is involved in the hepa-
tobiliary specification of hepatoblasts to cholangiocytes, 
and it is strongly expressed throughout the embryonic 
and adult biliary epithelium. Immunostaining of patients 
with advanced alcoholic liver disease showed that duct-
ular reaction cells were positive for HNF1β, whereas 
HNF1β was not expressed in mature hepatocytes [62]. 
It is demonstrate that HNF1β is expressed in liver pro-
genitor cells (LPC), and may also play a role in the main-
tenance of the hepatobiliary cell phenotype. Lineage 
tracing demonstrated that HNF1β+ cells give rise to the 
expansion of cells with a LPC phenotype and to peripor-
tal hepatocytes after liver injury [62]. Yu et  al. reported 
that the induced hepatic stem cells (iHepSCs) can be 
directly induced from mouse embryonic fibroblasts by 
overexpressing two key transcription factors, HNF1β 
and Foxa3 [63]. HNF1β has a critical role in the induc-
tion of iHepSCs. Pancreatic multipotent progenitor cells 
(MPCs) produce acinar, endocrine and duct cells during 
organogenesis [64]. HNF1β has been identified in these 
pancreatic progenitor cells before differentiation into 
endocrine or exocrine cells [65, 66]. Study showed that 
Sox9 directly bound to three genes, including HNF1β, 
HNF6, Foxa2, in  vitro and in intact cells, and regulated 
their expression. In turn, both Foxa2 and HNF1β regu-
lated Sox9 expression, demonstrating feedback circuits 
between these genes. Foxa2 (forkhead box protein A2), 
also known as HNF3β, is a member of the forkhead class 
of DNA-binding proteins. Foxa2 play an important role 
in the regulation of metabolism and in the differentia-
tion of the pancreas and liver. HNF6 is correlated to cell 
proliferation, differentiation and organogenesis, hepatic 
metabolism [5]. HNF1β, HNF6, and Foxa2 are simulta-
neously expressed in several regions in the early endo-
derm, including the developing gut and liver, and persist 
in the duct cells of the adult pancreas [65]. Transient 
knockdown of Sox9 levels by nearly 50  % resulted in a 
50  % increase in the expression of HNF1β [65]. HNF1β 
which is expressed before HNF6 in the endoderm, was 
found to be critical for HNF6 expression. HNF6 controls 
the initiation of the expression of pancreatic and duode-
nal homeobox 1 (Pdx1), the earliest marker of pancreatic 
precursor cells [67]. Therefore, the sequential activation 
of HNF1β, HNF6, and Pdx1 in the endoderm appears to 
control the generation of pancreatic precursors. Stud-
ies showed that Pdx1 contributed to the specification 
of pancreatic endocrine progenitors by participating in 
the Hnf6, Sox9, Hnf1β, Foxa2 transcription factor cross-
regulatory network and by regulating Ngn3 directly [68]. 
Ngn3 (neurogenin3) plays an important role in pancre-
atic development and the differentiation of endocrine 
cells. Ngn3 is also one of the pancreatic progenitor mark-
ers. Because HNF1β is required for Ptf1a expression in 
the developing pancreatic bud, Ptf1a may also be down-
stream of HNF1β when generating pancreatic precursors 
in the endoderm [67]. Ptf1a (pancreas transcription fac-
tor 1a) is expressed in early bud pancreatic multipotent 
progenitor cells, with an instructive role in distinguishing 
pancreatic fate from the adjacent organs [64]. All these 
studies showed that HNF1β is closely related to stem/
progenitor cells.
Conclusions
HNF1β plays an important role in tumorigenesis of vari-
ous organs. High expression of HNF1β showed worse 
survival in both pancreatic carcinoma and hepatocel-
ullar carcinoma. HNF1β expression is reduced in renal 
cell carcinoma compared with normal kidney tissue. 
HNF1β may functions as a tumor suppressor gene in 
renal cell carcinoma. In prostate cancer, the studies of 
HNF1β focus mainly on the single nucleotide polymor-
phisms. Genome-wide association studies have discov-
ered at least 30 susceptibility loci for prostate cancer. It is 
demonstrated that HNF1β would be an excellent marker 
for distinguishing CCCs from other lesions in both the 
ovary and the endometrium. In ovarian cancer, down-
regulation of HNF1β may contribute to drug resistance, 
thus estoration of HNF1β function could be a therapeu-
tic approach. Many genetic and epigenetic alterations 
of HNF1β gene as well as several genetic networks and 
signaling pathways that are considered to be involved in 
the development and progression of tumor. The details 
of the regulatory pathways and their mechanisms are still 
under investigation. Studies also showed that HNF1β is 
closely associated with stem/progenitor cells. However, 
the potential pathogenic mechanisms of HNF1β in can-
cer and regulatory mechanisms in stem cells are still less 
understood. Thus, further study for HNF1β with tumor 
and stem cell is still needed.
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